Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Antithrombotic therapy in 2014

Making headway in anticoagulant and antiplatelet therapy

Nature Reviews Cardiology volume 12, pages 70–71 (2015)Cite this article

Subjects

Despite favourable results in pivotal clinical trials involving novel direct oral anticoagulants, vitamin K antagonists remain the most commonly prescribed anticoagulant. Newer oral anticoagulants are slated for a wide range of additional indications, and specific antidotes to neutralize associated bleeding complications are currently under development.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The new-generation non-vitamin K anticoagulants that inhibit thrombin and factor Xa.

References

  1. Lip, G. Y. et al. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP–AF pilot survey. Am. J. Med. 127, 519–529 (2014).

    Article  Google Scholar 

  2. Wells, P. S., Forgie, M. A. & Rodger, M. A. Treatment of venous thromboembolism. JAMA 311, 717–728 (2014).

    Article  CAS  Google Scholar 

  3. Reilly, P. A. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J. Am. Coll. Cardiol. 63, 321–328 (2014).

    Article  CAS  Google Scholar 

  4. Siegal, D. M., Garcia, D. A. & Crowther, M. A. How I treat target-specific oral anticoagulant-associated bleeding. Blood 123, 1152–1158 (2014).

    Article  CAS  Google Scholar 

  5. Eerenberg, E. S. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573–1579 (2011).

    Article  CAS  Google Scholar 

  6. Schiele, F. et al. A specific antidote for dabigatran: Functional and structural characterization. Blood 121, 3554–3562 (2013).

    Article  CAS  Google Scholar 

  7. Lu, G. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19, 446–451 (2013).

    Article  CAS  Google Scholar 

  8. Ansell, J. E. et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N. Eng. J. Med. 371, 2141–2142 (2014).

    Article  Google Scholar 

  9. Mauri, L. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Eng. J. Med. 371, 2155–2166 (2014).

    Article  Google Scholar 

  10. Baker, N. C., Lipinski, M. J., Lhermusier, T. & Waksman, R. Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar. Circulation 130, 1287–1294 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, 2160 South 1st Avenue, Maywood, 60153, IL, USA

    Jawed Fareed

Authors
  1. Jawed Fareed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jawed Fareed.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fareed, J. Making headway in anticoagulant and antiplatelet therapy. Nat Rev Cardiol 12, 70–71 (2015). https://doi.org/10.1038/nrcardio.2014.222

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2014.222

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research